Mini Review - Annals of Clinical Trials and Vaccines Research (2022) Volume 12, Issue 6

Gestational Diabetes and Thyroid Autoimmunity

Christiaan Mooij*

Department of Pediatric Endocrinology, Emma Children’s Hospital, Amsterdam UMC, University of Amsterdam, Netherlands

*Corresponding Author:
Christiaan Mooij
Department of Pediatric Endocrinology, Emma Children’s Hospital, Amsterdam UMC, University of Amsterdam, Netherlands
Tel: +319820165234

Received: 28-Nov-2022, Manuscript No. actvr-22-83637; Editor assigned: 01-Dec-2022, PreQC No. actvr-22- 83637(PQ); Reviewed: 15-Dec- 2022, QC No. actvr-22-83637; Revised: 22-Dec-2022, Manuscript No. actvr-22-83637(R); Published: 30-Dec-2022; DOI: 10.37532/ ACTVR.2022.12(6).118-121


Similarities within the symptom course and alternative manifestations of some diseases could cause clinical misdiagnosis of COVID-19 infection. Here, we have a tendency to report a case in an exceedingly young kid with a doubtless confusing clinical course. A 29-monthold boy given with a 2-month history of fever, His PCR takes a look at for COVID-19 was positive, and there was serosa effusion and positive findings within the lower left lobe of the respiratory organ on computerized tomography scan. Mid-sized hypertrophy was found on abdominal ultrasound, and laboratory tests disclosed cytopenia. In light-weight of the atypical white blood corpuscle counts in laboratory tests, he underwent bone marrow aspiration. The urged identification was hemophagocytic lymphohistiocytosis, and Pediapred was initiated. Afterwards, Leishman-Donovan bodies were seen within the bone marrow aspirate, and treatment was started with antibiotic drug, that light-emitting diode to clinical improvement. In cases with imprecise clinical symptoms in tropical countries wherever alternative infectious diseases occur, doable synchronal infection ought to be thought of even throughout a plague. Familiarity with the doable differential diagnoses and acceptable, gradual thought to rule out alternative doable cause’s area unit required all told things, and therefore the existence of communicable disease ought to be thought of in evaluating the clinical conditions of patients in tropical countries.


Gestational diabetes • Overt hypothyroidism • Pre-eclampsia • Thyroid auto-immunity hypothyroidism • Persisting symptoms • Quality of life


Any degree of carbohydrate intolerance that is initially identified during pregnancy is referred to as gestational diabetes (GDM). Between 1% and 14% of women over 35 experience GDM during the second trimester of pregnancy, where it is most prevalent. Anti-glutamic-acid-decarboxylase (GAD-) 65 antibodies (GAD65-Ab) are frequently found in patients who require insulin therapy after delivery (less than 10% of patients), and in these circumstances, GDM is regarded as the beginning of type 1 diabetes. Patients with type1 diabetes have been shown to have an increased incidence of organ-specific autoimmunity to endocrine cells other than -cells, which are thought to be brought on by a hereditary predisposition to autoimmune diseases. However, it is thought that in the majority of patients, GDM is brought on by -cell dysfunction that takes place against a backdrop of on-going insulin resistance. Although GDM normally goes away in these patients after birth, up to 70% of them go on to develop overt type 2 diabetes mellitus within 10 years [1].

Thyroid autoimmunity is more common among type 2 diabetics, according to recent studies, suggesting that diabetes can cause thyroid autoimmune to develop. The frequency of thyroid dysfunction and autoimmune disease in women with GDM has only been examined in a few numbers of researches. In addition, thyroid autoimmunity in post- GDM patients is little understood, despite the fact that following delivery, normal glucose control is typically restored. We believe that GDM is a wonderful chance to investigate whether diabetes and hyperglycemia may be risk factors for thyroid autoimmunity. Therefore, we looked into two different areas in the current study: pancreatic and thyroid autoimmune in GDM patients and pancreatic and thyroid autoimmunity in women who had previously had GDM [2].

Materials and Methods

Recent research has shown that thyroid autoimmune disease is more prevalent among type 2 diabetics, indicating that diabetes may contribute to thyroid autoimmune disease development. Only a few studies have looked at the prevalence of thyroid dysfunction and autoimmune illness in women with GDM. In addition, despite the fact that adequate glucose control is frequently recovered after delivery, thyroid autoimmunity in post-GDM patients is poorly understood. We think that GDM is a fantastic opportunity to look at the possibility that thyroid autoimmunity may be increased by diabetes and hyperglycemia. In the present study, we therefore focused on two distinct areas: pancreatic and thyroid autoimmune in GDM patients and pancreatic and thyroid autoimmune in women with a history of GDM [3].

As previously mentioned, stimulating TSH receptor antibodies (TSHr-Abs) were estimated utilising a biological technique. In a nutshell, Chinese hamster ovary (CHO) cells underwent a two-stage double stable transfection. In the first step, the cells were transfected with a CRE-luc construct, making them extremely sensitive to changes in cAMP levels. The cells were transfected with wild-type human TSHr in the following step. These cells were kept alive in Ham’s F12 nonessential amino acids with 10% foetal calf serum, penicillin/streptomycin (1 U/mL/1 mg/mL, respectively), for 24 hours before being switched to starvation medium (Hank’s balanced salt solution with no foetal calf serum) for an additional 24 hours. Every cell was kept at 37 °C, 5% CO2, and 95% relative humidity. The mean of 5 samples from normal participants was used to define the cut-off for normal levels. The computed mean was increased by multiplying the determined standard deviation between these normal samples by two. This method’s cut-off value was arbitrarily determined to be equal to 1 unit (AU). Using the Bright-Glow reagent and a single-tube illuminometer to quantify the light output, the luciferase activity was discovered. Variability within and between assays was less than 5% [4].

The other 69 women (group B) had given birth between 18 and 120 months before to this study. They had undergone an OGTT evaluation during their pregnancy and were subsequently diagnosed as having GDM or not. These patients were subsequently separated into two groups for the study’s purposes. Women who had a history of thyroid disease or who had taken any medication known to affect the immune system or the thyroid were not allowed to participate in the trial. None of the participants in the study underwent a second evaluation, hence none of the patients in group A were also a part of group B. L-thyroxin was administered to all group A1 and A2 women who had increased TSH levels, and we individually assessed the option of treatment for group B1 women. Each study participant gave their informed consent before beginning the investigation [5].


Numerous studies have looked into the incidence of pancreatic autoimmunity in GDM, and it has been found to vary by race and location. In the current study, 3.3% of our population had GAD65-Abs, which is in line with multiple earlier publications. Since GAD autoantibodies have the highest diagnostic sensitivity in LADA, they should be utilised to identify such patients, hence in our investigation, we have solely looked at anti- GAD levels.

The prevalence of thyroid autoimmunity during GDM has been the subject of fewer studies; the majority of these failed to demonstrate a significant increase, though a few reports suggested that women with a family history of thyroid disorders and diabetes were more likely to develop thyroid autoimmunity. The current investigation also finds no appreciable variations. The mean TSH value of the GDM patients was comparable to that of typically pregnant women, and there were no differences between the two groups in terms of the prevalence of aberrant TSH values. The FT4 levels did not differ appreciably at the same time. Overall, it can be said that there were no abnormalities in thyroid function and autoimmunity between GDM patients and healthy pregnant women in the current study [6].

We know very little about the prevalence of thyroid autoimmunity in women who have had past GDM. We discovered that patients with prior GDM had higher rates of thyroid antibodies; in fact, 31.6% of our patients tested positive for TPO-Ab, Tg-Abs, or TSHr-Ab, compared to 9.7% of women with prior normal pregnancies. We should also note that the TSHr-Ab assay was the only tool that allowed us to diagnose thyroid autoimmunity in one case. Although GAD65- Abs were negative in our patients, and there is currently no requirement for insulin therapy, the existence of the TSHr-Ab has previously been described for a cohort of type 1 diabetes patients as the only indication of thyroid autoimmune. On the frequency of thyroid autoimmunity in women who have had previous GDM, little information is currently known. The prevalence of thyroid antibodies was higher in patients with prior GDM; in fact, 31.6% of these patients tested positive for TPO-Ab, Tg-Abs, or TSHr- Ab, compared to 9.7% of women with prior normal pregnancies. Furthermore, we would like to emphasise that in one patient, thyroid autoimmunity was only discovered by the TSHr-Ab assay. Since our patients’ GAD65- Abs were negative and there is currently no requirement for insulin therapy, the existence of the TSHr-Ab as the only indicator of thyroid autoimmunity has previously been reported for a cohort of type 1 diabetes patients.

The number of women who had previously given birth who also tested positive for Ab was higher (7/38 [18.4%] in group B1 and 1/31 [3.3%] in group B2]). Based on our findings, it may be hypothesised that post-GDM women experience an increase in thyroid autoimmunity, and that this phenomenon is significant enough to result in subclinical thyroid dysfunction. It has been widely documented that autoimmune diabetes (both type 1 and latent autoimmune diabetes) is associated with other organspecific autoimmune illnesses. In the current investigation, however, only 1 lady tested positive for both pancreatic and thyroid auto immunities [7].

The greater prevalence of thyroid autoimmunity in our post-GDM patients is therefore unlikely to be explained by a common (pancreatic and thyroid) autoimmune characteristic, It has been proposed that a shared antigen between pancreatic -cells and thyroid follicular cells is the cause of the clinical link between chronic autoimmune thyroiditis and type 2 diabetes. More recently, we have demonstrated that uncontrolled MHC class I expression can be caused by a 10 mM increase in glucose levels in cultured thyroid cells. In light of this, we proposed the hypothesis that this process makes the thyrocyte an antigen-presenting cell and may even help it to overcome selftolerance. In fact, studies using animal models have demonstrated that high amounts of MHC molecules, which enhance thyroid antigen presentation, might cause thyroid autoimmunity [8].

This observation led us to speculate that the autoimmune illness in our patients was brought on by hyperglycemia during pregnancy or right after delivery. If so, GDM offers a rare opportunity to examine the development of thyroid autoimmunity from its beginning. However, it must be underlined that the current research and our theoretical interpretation should only be viewed as a first step. OGTT with 100 g of glucose was used in our study to diagnose GDM, and as is well known, new diagnostic criteria proposed by IADPSG and ADA have just been introduced. We are unable to assess if the behaviour would have remained the same under new standards. The 4th International Workshop Conference criteria had previously classified a group of women as normal, but the new criteria for diagnosing GDM revealed metabolic characteristics and pregnancy outcomes similar to those of women who would have been diagnosed with gestational diabetes under the old criteria. In fact, this study’s main limitation is the very small number of participants it analysed. Therefore, to verify our data, observations on a larger population are required [9].

Since there were so few patients, statistical significance could not be reached, even though a higher proportion of patients with impaired glucose metabolism had thyroid Ab positivity (58.3% versus 42.3%). In this context, we also cannot rule out the possibility that progression towards hyperglycemic disease after delivery could further facilitate the onset of thyroid autoimmune disease. In a 20-year follow-up, Männistö and colleagues demonstrated that the presence of overt hypothyroidism increases the risk of diabetes rather than the presence of thyroid antibodies [10].


On the other hand, the development of GDM is not influenced by the presence of TPO-Ab. In fact, a major study with over 600 pregnant women found that GDM was present in 8.1% of the women who had TPO-antibody positive as opposed to 6.8% of the women who did not, and that this difference was not statistically significant. Among conclusion, the primary new result of our study is the increased frequency of thyroid autoimmunity and thyroid dysfunction in women who have had prior GDM. We hypothesise that thyroid autoimmune disease may be brought on by gestational hyperglycemia.

Conflict of Interests





  1. Cianni G. Diagnosis and classification of diabetes mellitus (Position Statement). Diabetes Care. 34:62-69 (2011).
  2. Google Scholar , Crossref, Indexed at

  3. King H. Epidemiology of glucose intolerance and gestational-diabetes in women of childbearing age. Diabetes Care. 21:9-13 (1998).
  4. Google Scholar , Indexed at

  5. Lapolla A, Dalfrà MG, Lencioni C et al. Epidemiology of diabetes in pregnancy. Diabetes Metab J. 17:358-367 (2004).
  6. Google Scholar , Crossref, Indexed at

  7. Buchanan TA, Xiang AH. Gestational diabetes mellitus. J Clin Invest. 115:485-491 (2005).
  8. Google Scholar , Crossref, Indexed at

  9. Lapolla A, Fedele D, Pedini B et al. Low frequency of autoantibodies to islet cell, glutamic acid decarboxylase, and second-islet antigen in patients with gestational diabetes mellitus. Ann N Y Acad Sci. 958:263-266 (2002).
  10. Google Scholar , Crossref, Indexed at

  11. Carpenter MW, Coustan DR. Criteria for screening tests for gestational diabetes. Am J Obstet Gynecol. 144:768-773 (1982).
  12. Google Scholar , Crossref, Indexed at

  13. Lapolla A, Dalfra MG, Fedele D et al. Diabetes related autoimmunity in gestational diabetes mellitus: is it important? Nutr Metab Cardiovasc Dis. 19:674-682 (2009).
  14. Google Scholar , Crossref, Indexed at

  15. Gambelunghe G, Forini F. Increased risk for endocrine autoimmunity in Italian type 2 diabetic patients with GAD65 autoantibodies. Clin Endocrinol News. 52:565-573 (2000).
  16. Google Scholar , Crossref, Indexed at

  17. Laureti S. Recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 33:676-682 (2010).
  18. Google Scholar , Crossref, Indexed at

  19. Montaner P, Juan J, Campos R et al. Is thyroid autoimmunity associated with gestational diabetes mellitus? Metabolism. 57:522-525 (2008).
  20. Google Scholar , Crossref, Indexed at